Cinnagen
You can help expand this article with text translated from the corresponding article in Persian. (January 2022) Click [show] for important translation instructions.
|
CinnaGen is an
recombinant proteins, and exported to other countries in the Middle East and to countries in the Commonwealth of Independent States.[1]
: 70
One of CinnaGen's products is Cinnovex, a biosimilar of
Fraunhofer Institute in Germany which also conducted the initial testing; Fraunhofer licensed it to CinnaGen which completed development and obtained approval from Iranian Food and Drug Administration in 2007.[2][3]
In a new cooperation agreement, Phases 2 and 3 clinical trials of the Vaxine’s monovalent recombinant COVID-19 vaccine will be initiated in Iran in the coming weeks. If these studies are successful, this Australian vaccine will be produced under the brand name “SpikoGen Archived 2022-07-07 at the Wayback Machine®” by CinnaGen Company and will be rolled out in Iran[4]
See also
- COVAX-19 (SpikoGen)
- Pharmaceuticals in Iran
- Science and technology in Iran
References
- ^ Science, Technology and Innovation Policy Review: Iran (PDF). United Nations Conference on Trade and Development. 2016.
- ^ "Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran)". Wiener Zeitung (in German). 2007-03-20.
- ^ "Erstes biogenerisches therapeutisches Protein aus Fraunhofer-Labor für den Markt zugelassen". BioRegio STERN (in German). 2007-01-19. Archived from the original on 2017-10-20. Retrieved 2017-10-20.
- ^ ""SpikoGen®", a joint venture between Vaxine and CinnaGen – Vaxine". Archived from the original on 2021-07-11. Retrieved 2021-05-28.